The compelling case for anti-CD3 in type 1 diabetes

Diabetes

Volumn 62, Issue 11, 2013, Pages 3656-3657

  Skyler, Jay S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; MONOCLONAL ANTIBODY CD3; OTELIXIZUMAB; TEPLIZUMAB; MONOCLONAL ANTIBODY;

DRUG DOSE REDUCTION; DYSGLYCEMIA; EPSTEIN BARR VIRUS; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LATENT PERIOD; NOTE; PANCREAS ISLET CELL FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; FEMALE; MALE; METABOLISM; DIABETES MELLITUS, TYPE 1;

ANTIBODIES, MONOCLONAL, HUMANIZED; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE;

EID: 84891671479     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1157     Document Type: Note

References (18)

1. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
2. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3g1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769
3. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608
4. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-623
5. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497
6. Hagopian W, Ferry RJ Jr, Sherry N, et al.; for the Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-3908
7. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013;56:391-400
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
9. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
10. Herold KC, Gitelman SE, Ehlers MR, et al.; the AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766-3774
11. Bach JF. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011;378:459-460
12. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-127
13. U.S. National Institutes of Health. Teplizumab for prevention of type 1 diabetes in relatives "at-risk." [Internet], 2013. Available from http://www.clinicaltrials.gov/ct2/show/NCT01030861. Accessed 13 July 2013
14. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 11 May 2013 [Epub ahead of print]
15. Keymeulen B, Candon S, Fafi-Kremer S, et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010;115: 1145-1155
16. Sprangers B, Van der Schueren B, Gillard P, Mathieu C. Otelixizumab in the treatment of type 1 diabetes mellitus. Immunotherapy 2011;3:1303-1316
17. Gottlieb P, Pozzilli P. DEFEND-1: durable response therapy evaluation for early or new-onset type 1 diabetes. Oral presentation at the 71st Scientific Sessions of the American Diabetes Association, June 28, 2011, at the San Diego Convention Center, San Diego, California
18. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073